The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
High response rates with bevacizumab, docetaxel, and carboplatin in patients with HER2-negative advanced breast cancer: An experience of 22 case reports.
G. Tellez-Trevilla
No relevant relationships to disclose
P. Cabrera-Galeana
No relevant relationships to disclose
E. Gomez-Plata
No relevant relationships to disclose
J. L. Barrera-Franco
No relevant relationships to disclose
H. Astudillo
No relevant relationships to disclose